Structured exercise after chemotherapy lowers colon cancer recurrence and boosts long-term survival, new trial shows.
The European Medicines Agency has confirmed suspension of marketing authorization for Pfizer's now-withdrawn Oxbryta for ...
Pembrolizumab (Keytruda) administered before and after surgery reduced the risk of death by 26% vs placebo in patients with early-stage non–small cell lung cancer (NSCLC), according to 5-year ...
Physicians and patient advocacy groups are rallying behind a renewed legislative effort in Congress to amend what they claim ...
Atezolizumab improved DFS and OS in ctDNA-positive MIBC patients, with a median DFS of 9.9 months vs 4.8 months for placebo. Serial ctDNA testing may offer a more accurate assessment of MRD and early ...
Botox is widely known to iron out wrinkles, but it could also help ease phantom limb pain in Ukrainian war amputees, ...
From restricting blood flow to inhaling deadly gas, cycling’s latest ‘hacks’ blur the line between innovation and insanity.
In the UK, a massive 15 million of us think we drink too much. That's right - more than one in five Brits are concerned about ...
But these days, everyday folks, influencers and medical experts alike are talking about the many frustrating symptoms ...
After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to ...
Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...
Researchers at the ESMO Congress said they want to confirm their findings in a prospective randomized controlled trial.